AUROBINDO PHARMA
|
|
BOM : 524804     NSE : AUROPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Oct 11,2024 |
Price(EOD): ₹ 1,495.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 86,852.83 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | 2% | -0.8% | 60.9% |
SUN PHARMACEUTICAL INDUSTRIES | -0.2% | 3% | 68% |
CIPLA | -1.8% | -2% | 39.6% |
DR REDDYS LABORATORIES | -0.1% | -0.2% | 19.8% |
ZYDUS LIFESCIENCES | 1.4% | -4.2% | 76% |
DIVIS LABORATORIES | 13.7% | 12.9% | 60.4% |
FUNDAMENTAL ANALYSIS OF AUROBINDO PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AUROBINDO PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
24.58
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 3,533.22 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 2.91
P/B Calculated based on Book Value of Rs 29,842.80 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.92
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 29,718.40 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
116% 19% 35% |
SHARE PRICE MOMENTUM OF AUROBINDO PHARMA
AUROBINDO PHARMA vs SENSEX
DEBT OF AUROBINDO PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.14 0.23 0.11 0.16 |
0.21 0.18 0.1 0.16 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF AUROBINDO PHARMA
Pledged Promoter Shares |
18.9 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF AUROBINDO PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-0.17% -3.18% 6.66% -0.04% |
10.46% 40.66% 62.64% 60.63% |
QtrlyTrend |
2 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
AUROBINDO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2% | 1.4% | 58.4% |
S&P BSE MIDCAP SELECT INDEX | 1.6% | 0.4% | 53.6% |
S&P BSE MIDSMALLCAP | 1.1% | -0.1% | 50.3% |
S&P BSE MID CAP | 1.1% | -0.4% | 51% |
S&P BSE 400 MIDSMALLCAP | 1% | -0.3% | 48% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY PHARMA | 2.1% | 1.4% | 55.9% |
NIFTY HEALTHCARE | 2% | 1.8% | 55.4% |
NIFTY FREE MIDCAP 100 | 1.3% | 0.3% | 47% |
NIFTY MIDCAP150 | 1.2% | 0.6% | 45.9% |
NIFTY MID SMALL400 | 1.2% | 0% | 46.6% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA
Is AUROBINDO PHARMA good for long term investment?
As on Oct 11,2024, the Fundamentals of AUROBINDO PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of AUROBINDO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AUROBINDO PHARMA UnderValued or OverValued?
As on Oct 11,2024, AUROBINDO PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of AUROBINDO PHARMA ?
As on Oct 11,2024, the Intrinsic Value of AUROBINDO PHARMA is Rs. 1,109.57 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 693.04
Fair Value [Median EV / Sales Model] : Rs. 1,257.42
Fair Value [Median Price / Sales Model] : Rs. 1,109.57
Estimated Median Fair Value of AUROBINDO PHARMA : Rs. 1,109.57
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.